Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Enterprise Value: 2021-2025

Historic Enterprise Value for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $2.3 billion.

  • Kiniksa Pharmaceuticals International's Enterprise Value rose 64.19% to $2.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 117.09%. This contributed to the annual value of $1.2 billion for FY2024, which is 15.30% up from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Enterprise Value of $2.3 billion as of Q3 2025, which was up 47.17% from $1.6 billion recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's Enterprise Value's 5-year high stood at $2.3 billion during Q3 2025, with a 5-year trough of $459.1 million in Q1 2022.
  • In the last 3 years, Kiniksa Pharmaceuticals International's Enterprise Value had a median value of $1.1 billion in 2024 and averaged $1.2 billion.
  • Its Enterprise Value has fluctuated over the past 5 years, first crashed by 46.29% in 2022, then surged by 69.44% in 2024.
  • Quarterly analysis of 5 years shows Kiniksa Pharmaceuticals International's Enterprise Value stood at $628.6 million in 2021, then spiked by 35.37% to $851.0 million in 2022, then increased by 20.73% to $1.0 billion in 2023, then rose by 15.30% to $1.2 billion in 2024, then surged by 64.19% to $2.3 billion in 2025.
  • Its Enterprise Value stands at $2.3 billion for Q3 2025, versus $1.6 billion for Q2 2025 and $1.2 billion for Q1 2025.